Xiaorong R. Zhong
Chengdu, 610041, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 84 publications
CAT-WSI: Context-Aware Trajectory Learning for Whole-Slide Breast Pathology Segmentation.
Journal: IEEE transactions on medical imaging
Published: August 07, 2026
Advancement of subtype-based early breast cancer systematic therapy
Journal: Zhonghua yi xue za zhi
Published: July 21, 2026
Clinical application of PI3K/AKT/mTOR pathway testing in breast cancer
Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology
Published: March 08, 2026
Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis.
Journal: Signal transduction and targeted therapy
Published: February 19, 2025
Long-term outcomes of skin-sparing mastectomy and nipple-sparing mastectomy versus traditional mastectomy in breast cancer: a case-control study based on preoperative ultrasound and clinical indicators.
Journal: World journal of surgical oncology
Published: November 24, 2024
A whole slide image-based risk score predicts prognosis and postmastectomy radiotherapy benefit in triple negative breast cancer patients.
Journal: Scientific reports
Published: November 23, 2024
Integrating ultrasound radiomics and clinicopathological features for machine learning-based survival prediction in patients with nonmetastatic triple-negative breast cancer.
Journal: BMC cancer
Published: November 09, 2024
Development and validation of a 10-gene signature for predicting recurrence risk in HR+/HER2- early breast cancer undergoing chemo-endocrine therapy.
Journal: Breast (Edinburgh, Scotland)
Published: August 07, 2024
Multimodal recurrence risk prediction model for HR+/HER2- early breast cancer following adjuvant chemo-endocrine therapy: integrating pathology image and clinicalpathological features.
Journal: Breast cancer research : BCR
Published: July 30, 2024
Prognostic significance of ER-to-PR difference in ER+/HER2- early breast cancer.
Journal: Scientific reports
Published: July 16, 2024
DDX58 deficiency leads to triple negative breast cancer chemotherapy resistance by inhibiting Type I IFN-mediated signalling apoptosis.
Journal: Frontiers in oncology
Published: December 16, 2023
Efficacy and safety of tucidinostat in patients with advanced hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: real-world insights.
Journal: Annals of translational medicine
Published: October 27, 2023
Last Updated: 09/26/2026